Pembrolizumab alone or combined with chemotherapy versus chemotherapy for the treatment of metastatic cancer: A meta-analysis of randomized clinical trials
Yumin Yue, Quan Wang, Mingtian Wei, Fanghui Ding, Jiang Li, Bobo Zheng · 2024
Read Pembrolizumab alone or combined with chemotherapy versus chemotherapy for the treatment of metastatic cancer: A meta-analysis of randomized clinical trials by Yumin Yue, Quan Wang, Mingtian Wei, Fanghui Ding, Jiang Li, Bobo Zheng (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11651430.txt.
Description
Yumin Yue and co-authors present a 2024 meta-analysis comparing a cancer immunotherapy drug with chemotherapy for cancer that has spread. The drug, pembrolizumab, can be given alone or added to chemotherapy. Doctors disagreed on which plan helps patients most. The team pooled randomized trials that tested the drug against chemotherapy alone, searching databases through late 2023.
Sixteen trials with 9,148 patients met their rules. The drug alone lengthened survival and caused fewer severe side effects, though it raised immune-related ones. The drug plus chemotherapy lengthened survival and slowed the disease more clearly. Patients whose tumors scored high on a marker called PD-L1 gained the most. The authors note the drug's worth in tumor types not yet tested stays unclear.
Catalog record
| CREATOR | Yumin Yue, Quan Wang, Mingtian Wei, Fanghui Ding, Jiang Li, Bobo Zheng |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |